QuinStreet, Inc. (NASDAQ:QNST)
QuinStreet Inc, is a provider of online direct marketing and media services. The Company offers online messaging, email broadcasting, search engine marketing, and brand management services. It caters to education, financial services, healthcare, advertising, and tourism sectors. QuinStreet, Inc. also operates web portal which offers comprehensive consumer information service and companion insurance brokerage service to self-directed insurance shoppers. The Company vigilantly manages brand and regulatory compliance using proprietary technologies and staff. It does not support or use spyware, spam, or promotions that cheat customers. QuinStreet Inc. is headquartered in Foster City, California.
QuinStreet, Inc. (NASDAQ:QNST)’s Financial Overview
QuinStreet, Inc. (NASDAQ) surged 1.96% yesterday to close its trading session at $14.06. The company has 1 year Price Target of $20. QuinStreet, Inc. has 52-Week high of $20.02 and 52-Week Low of $9.76. The stock touched its 52-Week High on 20.02 and 52-Week Low on 9.76. The stock traded with the volume of 1.56 Million shares yesterday. The firm shows the market capitalization of $869.33 Million.
QuinStreet, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.14/share against the analyst consensus estimate of $0.13/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 7.7%.
The firm is trading with SMA20 of -21.31 Percent, SMA50 of -16.96 Percent and SMA200 of -4.43 percent. QuinStreet, Inc. has P/S value of 2.02 while its P/B value stands at 4.48. Similarly, the company has Return on Assets of 7.6 percent, Return on Equity of 11.4 percent and Return on Investment of 10.2 Percent. The company shows Gross Margin and Operating Margin of 14.7 percent and 3.6 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 5 analysts offering 12-month price forecasts for Quinstreet Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 19.00. The median estimate represents a +42.25% increase from the last price of 14.06.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
GW Pharmaceuticals Plc (NASDAQ:GWPH)
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
GW Pharmaceuticals Plc (NASDAQ:GWPH)’s Financial Outlook
The 12 analysts offering 12-month price forecasts for GW Pharmaceuticals PLC have a median target of 179.50, with a high estimate of 221.00 and a low estimate of 134.00. The median estimate represents a +18.65% increase from the last price of 151.29.
GW Pharmaceuticals Plc is expected* to report earnings on 02/26/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $-2.97. The reported EPS for the same quarter last year was $-2.43.
According to Zacks Investment Research, GW Pharmaceuticals Plc has a Consensus Recommendation of 1.25. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 0.71% and closed its last trading session at $151.29. The company has the market capitalization of $3.98 Billion. The stock has 52-week high of $179.65 and 52-Week low of $90.14. The firm touched its 52-Week high on 179.65 and 52-Week low on 90.14. The company has volume of 344720 shares. The company has a total of 26.32 Million shares outstanding.
GW Pharmaceuticals Plc (NASDAQ) in the last quarter reported its actual EPS of $-2.76/share where the analyst estimated EPS was $-2.51/share. The difference between the actual and Estimated EPS is $-0.25. This shows a surprise factor of -10 percent.
The company has YTD performance of 55.34 percent. Beta for GW Pharmaceuticals Plc stands at 2.79 while its ATR (average true range) is 5.62. The company has Weekly Volatility of 4.07%% and Monthly Volatility of 3.83%%.
GW Pharmaceuticals Plc has distance from 20-day Simple Moving Average (SMA20) of 7.22%, Distance from 50-Day Simple Moving Average of 21.07 percent and Distance from 200-Day Simple Moving Average of 8.3%.
The Company currently has ROA (Return on Assets) of -46.1 percent, Return on Equity (ROE) of -52.7 Percent and Return on Investment (ROI) of -67.8% with Gross margin of 66.9 percent and Operating & Profit margin of 0% and 0% respectively.